Katherine L. Baker-Neblett

2.1k total citations · 1 hit paper
17 papers, 1.4k citations indexed

About

Katherine L. Baker-Neblett is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Katherine L. Baker-Neblett has authored 17 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Katherine L. Baker-Neblett's work include Renal cell carcinoma treatment (7 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Katherine L. Baker-Neblett is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Katherine L. Baker-Neblett collaborates with scholars based in United States, United Kingdom and Australia. Katherine L. Baker-Neblett's co-authors include Lini Pandite, Thomas E. Hutson, Robert A. Figlin, Michael Stocum, William Spreen, Arlene R. Hughes, Seth Hetherington, Mary E. Fling, Linda M. Thurmond and Denise Shortino and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Katherine L. Baker-Neblett

17 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

2002 583 citations Seth Hetherington, Arlene R. Hughes et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katherine L. Baker-Neblett United States	12	581	553	357	331	328	17	1.4k
Markku H. Vaarala Finland	22	552 1.0×	572 1.0×	220 0.6×	23 0.1×	286 0.9×	53	1.5k
Steven Blotner United States	17	223 0.4×	257 0.5×	177 0.5×	39 0.1×	598 1.8×	36	1.1k
Qingzhu Jia China	21	551 0.9×	628 1.1×	418 1.2×	30 0.1×	971 3.0×	55	2.4k
George H. Barrows United States	20	613 1.1×	399 0.7×	249 0.7×	41 0.1×	630 1.9×	40	1.9k
Yosuke Shimizu Japan	24	741 1.3×	483 0.9×	206 0.6×	48 0.1×	403 1.2×	144	1.6k
Enzo Maria Ruggeri Italy	22	535 0.9×	274 0.5×	279 0.8×	50 0.2×	681 2.1×	103	1.4k
John H. Saiki United States	17	313 0.5×	272 0.5×	67 0.2×	155 0.5×	568 1.7×	29	1.4k
Robert W. Mutter United States	22	418 0.7×	374 0.7×	483 1.4×	68 0.2×	523 1.6×	84	1.6k
Francesco Schettini Italy	22	641 1.1×	493 0.9×	463 1.3×	20 0.1×	861 2.6×	113	2.0k
Kristen A. Marrone United States	16	761 1.3×	458 0.8×	190 0.5×	54 0.2×	1.5k 4.5×	74	2.0k

Countries citing papers authored by Katherine L. Baker-Neblett

Since Specialization

Citations

This map shows the geographic impact of Katherine L. Baker-Neblett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine L. Baker-Neblett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine L. Baker-Neblett more than expected).

Fields of papers citing papers by Katherine L. Baker-Neblett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine L. Baker-Neblett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine L. Baker-Neblett. The network helps show where Katherine L. Baker-Neblett may publish in the future.

Co-authorship network of co-authors of Katherine L. Baker-Neblett

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine L. Baker-Neblett. A scholar is included among the top collaborators of Katherine L. Baker-Neblett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine L. Baker-Neblett. Katherine L. Baker-Neblett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Morgensztern, Daniel, Nina Karaseva, Enriqueta Felip, et al.. (2019). An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer. 136. 74–79. 19 indexed citations

Pritchett, Michael A., D. Ross Camidge, Samir Dalia, et al.. (2019). Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. JCO Precision Oncology. 3(3). 1–15. 36 indexed citations

Choueiri, Toni K., André P. Fay, Robert Gagnon, et al.. (2013). The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. Clinical Cancer Research. 19(18). 5218–5226. 73 indexed citations

Baker-Neblett, Katherine L., Andrij Baumketner, Yu‐Chun Lin, et al.. (2012). ICSM: An order method for calculating electrostatic interactions added to TINKER. Computer Physics Communications. 184(1). 19–26. 3 indexed citations

Tran, Hai T., Yuan Liu, Amado J. Zurita, et al.. (2012). Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. The Lancet Oncology. 13(8). 827–837. 204 indexed citations

Grilley‐Olson, Juneko E., Angelica Fasolo, Samuel C. Blackman, et al.. (2011). Abstract B155: A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). B155–B155. 2 indexed citations

Xu, Chun‐Fang, Zhengyu Xue, Li Huang, et al.. (2010). Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. British Journal of Cancer. 102(9). 1371–1377. 99 indexed citations

Tran, Hang, Yen‐Ting Lin, Katherine L. Baker-Neblett, et al.. (2010). Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients.. Journal of Clinical Oncology. 28(15_suppl). 4522–4522. 6 indexed citations

Erickson‐Miller, Connie L., Kodandaram Pillarisetti, Katherine L. Baker-Neblett, et al.. (2010). Thrombopoietin Receptor Levels in Tumor Cell Lines and Primary Tumors. Journal of Oncology. 2010. 1–8. 9 indexed citations

10.

Hutson, Thomas E., Ian D. Davis, Jean‐Pascal Machiels, et al.. (2009). Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 28(3). 475–480. 229 indexed citations

11.

Heymach, John V., Hai T. Tran, Herbert A. Fritsche, et al.. (2009). Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib. Molecular Cancer Therapeutics. 8(12_Supplement). A11–A11. 5 indexed citations

12.

McGillivray, Jane & Katherine L. Baker-Neblett. (2008). Effects of Comorbid ADHD with Learning Disabilities on Anxiety, Depression, and Aggression in Adults. Journal of Attention Disorders. 12(6). 525–531. 17 indexed citations

13.

Hutson, Thomas E., Ian D. Davis, J. H. Machiels, et al.. (2008). Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. Journal of Clinical Oncology. 26(15_suppl). 5046–5046. 67 indexed citations

14.

Hutson, Thomas E., Ian D. Davis, J-P. Machiels, et al.. (2007). Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology. 25(18_suppl). 5031–5031. 53 indexed citations

15.

Wire, Mary Beth, et al.. (2006). Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV. Antimicrobial Agents and Chemotherapy. 50(4). 1578–1580. 11 indexed citations

16.

Ford, Susan L., Mary Beth Wire, Yu Lou, Katherine L. Baker-Neblett, & Daniel S. Stein. (2004). Effect of Antacids and Ranitidine on the Single-Dose Pharmacokinetics of Fosamprenavir. Antimicrobial Agents and Chemotherapy. 49(1). 467–469. 33 indexed citations

17.

Hetherington, Seth, Arlene R. Hughes, Michael Mosteller, et al.. (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. The Lancet. 359(9312). 1121–1122. 583 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact